LB PHARMACEUTICALS INC - 8-K Filing
LB Pharmaceuticals reported Q1 2026 financial results with a net loss of $19.1 million (vs. $5.3M in the same period last year), driven by increased R&D expenses ($14.6M) and G&A costs ($7.5M). The company holds $365.6 million in cash, which it expects to fund operations through Q2 2029. It also announced clinical progress for LB-102: initiation of the pivotal Phase 3 NOVA-2 trial in schizophrenia (topline data expected H2 2027) and a $100M private placement completed in February 2026. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $LBRX